AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12869081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients already receiving antibiotics for prior indications
Number of subjects: 141
Study 12869081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 10531745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated implants
Number of subjects: 0
Study 10531745 — intervention group
Group type: COMPARATOR
Intervention: Non-coated commercially pure titanium implants
Number of subjects: 0
Study 10159954 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hyperimmune therapy
Number of subjects: 0
Study 8495871 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative start of thromboprophylaxis with low molecular weight heparin
Number of subjects: 0
Study 8495871 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3086899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate 40 mg twice daily
Number of subjects: 29
Study 3086899 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release isosorbide dinitrate 40 mg twice daily
Number of subjects: 29
Study 29485019 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed hand hygiene (DOHH) performed at two-hourly intervals during daytime, before meals and medication rounds by a trained nurse.
Number of subjects: 10
Study 29485019 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of alcohol-based hand rub (ABHR) consumed per resident per week in the intervention arm.
Number of subjects: 10
Study 29485019 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group (no DOHH).
Number of subjects: 10
Study 27401505 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals-of-care (GoC) intervention
Number of subjects: 80
Study 27401505 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instructions for APS‐R
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation prompting normal distribution consideration
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog (slider) scale for APS‐R
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical transformations of perfectionism scores
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion indicators of emotion regulation (reappraisal or suppression), perceived stress, and depression
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive perfectionists
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive perfectionists
Number of subjects: 506
Study 25111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both perfectionist classes
Number of subjects: 506
Study 22180390 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality cognitive-behavior therapy (VRCBT)
Number of subjects: 88
Study 22180390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 88
Study 22180390 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 88
Study 20143246 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 25 mg/day
Number of subjects: 0
Study 18677327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (part of a 4-year randomized controlled trial)
Number of subjects: 23
Study 16447471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensiometer feedback combined with subjective feedback
Number of subjects: 12
Study 16447471 — intervention group
Group type: COMPARATOR
Intervention: Subjective feedback only
Number of subjects: 12
Study 16447471 — intervention group
Group type: COMPARATOR
Intervention: Tensiometer feedback only
Number of subjects: 12
Study 16447471 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 12
Study 12860210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 45
Study 10368853 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 lux light for 3 hours prior to awakening for 12 days
Number of subjects: 10
Study 10368853 — intervention group
Group type: COMPARATOR
Intervention: 0.1 lux light for 3 hours prior to awakening for 12 days (Placebo)
Number of subjects: 10
Study 8683230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 764
Study 8683230 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg once daily
Number of subjects: 764
Study 8683230 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg four times daily
Number of subjects: 764
Study 1874767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefonicid (Group I)
Number of subjects: 1489
Study 1874767 — intervention group
Group type: COMPARATOR
Intervention: Three doses of cefamandole (Group II)
Number of subjects: 1489
Study 1874767 — intervention group
Group type: COMPARATOR
Intervention: Five doses of cefamandole (Group III)
Number of subjects: 1489
Study 7097431 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral conditioning with a urine alarm
Number of subjects: 0
Study 7097431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with imipramine hydrochloride
Number of subjects: 0
Study 7097431 — intervention group
Group type: COMPARATOR
Intervention: Clinical waiting list (control group)
Number of subjects: 0
Study 31247461 — intervention group
Group type: EXPERIMENTAL
Intervention: AgFON substrate for SERS detection
Number of subjects: 0
Study 27792112 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intermittent bolus epidural analgesia (PCIEA)
Number of subjects: 47
Study 27792112 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled continuous epidural analgesia (PCCEA)
Number of subjects: 47
Study 27792112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 47
Study 25938174 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded group (BG)
Number of subjects: 9
Study 25938174 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire group (WG)
Number of subjects: 9
Study 25938174 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 9
Study 25938174 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded group (BG) vs Wire group (WG)
Number of subjects: 9
Study 25938174 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded group (BG) and Wire group (WG)
Number of subjects: 9
Study 24373641 — intervention group
Group type: EXPERIMENTAL
Intervention: DexNP (dexamethasone nanoparticle eye drops)
Number of subjects: 6
Study 24373641 — intervention group
Group type: EXPERIMENTAL
Intervention: DorzNP (dorzolamide nanoparticle eye drops)
Number of subjects: 6
Study 24373641 — intervention group
Group type: COMPARATOR
Intervention: Maxidex(®) (dexamethasone control)
Number of subjects: 6
Study 24373641 — intervention group
Group type: COMPARATOR
Intervention: Trusopt(®) (dorzolamide control)
Number of subjects: 6
Study 23102530 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction (CS)
Number of subjects: 20
Study 23102530 — intervention group
Group type: COMPARATOR
Intervention: Open suction (OS)
Number of subjects: 20
Study 19545211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine dose of 1 X 10(4) ffu
Number of subjects: 369
Study 19545211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine dose of 1 X 10(5) ffu
Number of subjects: 369
Study 19545211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 17311544 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable Xenon enhanced computed tomography (Xe‐CT)
Number of subjects: 8
Study 17311544 — intervention group
Group type: COMPARATOR
Intervention: Group B (severely disabled, persistent vegetative state)
Number of subjects: 8
Study 17311544 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (good recovery)
Number of subjects: 8
Study 15302293 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 850 mg two times per day
Number of subjects: 38
Study 15302293 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle modification plus metformin 850 mg two times per day
Number of subjects: 38
Study 15302293 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle modification plus placebo
Number of subjects: 38
Study 15302293 — intervention group
Group type: COMPARATOR
Intervention: placebo alone
Number of subjects: 38
Study 11591495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (transdermal administration)
Number of subjects: 20
Study 11591495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9643401 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine adoption of HIV infection control guidelines during delivery (including protective glasses, impermeable garments, mask, sterile latex gloves, washing hands with detergent solution after using gloves, and collecting needles in suitable containers)
Number of subjects: 752
Study 9643401 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of latex gloves and collecting needles in suitable containers
Number of subjects: 752
Study 9643401 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing hands after using gloves
Number of subjects: 752
Study 9643401 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective impermeable garments, glasses, and mask
Number of subjects: 752
Study 8036463 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole treatment (40-160 mg daily)
Number of subjects: 11
Study 8036463 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole treatment
Number of subjects: 11
Study 2657056 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 10
Study 2657056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1194526 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation to anger with opportunity for retaliation
Number of subjects: 60
Study 1194526 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation to anger with no opportunity to retaliate
Number of subjects: 60
Study 1194526 — intervention group
Group type: COMPARATOR
Intervention: No provocation, no retaliation (control group)
Number of subjects: 60
Study 31926854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 4396
Study 31926854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4396
Study 31092443 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m2) plus cisplatin (80 mg/m2) with bevacizumab (15 mg/kg) followed by maintenance with bevacizumab plus S-1 (SCB)
Number of subjects: 48
Study 31092443 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) with bevacizumab (15 mg/kg) followed by maintenance with bevacizumab plus pemetrexed (PCB)
Number of subjects: 48
Study 28079781 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 138
Study 28079781 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 138
Study 28079781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 25076118 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 20
Study 25076118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23724543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 15% with light activation (Lase Peroxide Lite)
Number of subjects: 88
Study 23724543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 35% with light activation (Lase Peroxide Sensy)
Number of subjects: 88
Study 23724543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide at 35% without light activation (Whitegold Office)
Number of subjects: 88
Study 21777229 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40-60 mg/day for 2 weeks)
Number of subjects: 148
Study 18423165 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli isolates
Number of subjects: 3109
Study 18423165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin resistance
Number of subjects: 3109
Study 18423165 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing E. coli
Number of subjects: 3109
Study 18423165 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance rates of ESBL-producing E. coli
Number of subjects: 3109
Study 16978561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation for 12 weeks and programme maintenance for 24 months
Number of subjects: 56
Study 16978561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation for 12 weeks without maintenance programme
Number of subjects: 56
Study 16978561 — intervention group
Group type: COMPARATOR
Intervention: Customary care (Control group)
Number of subjects: 56
Study 12874094 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 29
Study 12874094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11507793 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple baseline time-series design
Number of subjects: 0
Study 11507793 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted time-series experiments
Number of subjects: 0
Study 11507793 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analyses of time-series data
Number of subjects: 0
Study 9191638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicortical noncompressive screws (S1, n = 15; S2, n = 15)
Number of subjects: 60
Study 9191638 — intervention group
Group type: COMPARATOR
Intervention: Unicortical screws and miniplates (P1, n = 15; P2, n = 15)
Number of subjects: 60
Study 9191638 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 60
Study 9191638 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-angle cases (ML/NSL < 25 degrees)
Number of subjects: 60
Study 9191638 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of surgical advancement
Number of subjects: 60
Study 1439646 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐stat group (with carbon dioxide)
Number of subjects: 12
Study 1439646 — intervention group
Group type: COMPARATOR
Intervention: alpha‐stat group (without carbon dioxide)
Number of subjects: 12
Study 3533674 — intervention group
Group type: EXPERIMENTAL
Intervention: Miraxid (pivmecillinam 200 mg plus pivampicillin 250 mg)
Number of subjects: 388
Study 3533674 — intervention group
Group type: COMPARATOR
Intervention: Augmentin (amoxycillin 250 mg plus clavulanic acid 125 mg)
Number of subjects: 388
Study 3533674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 388
Study 31620856 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 30 ml 0.25% bupivacaine
Number of subjects: 56
Study 31620856 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as placebo (control group)
Number of subjects: 56
Study 28514053 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-guided interventions (Precaution Adoption Process Model or Authoritative Parenting Model)
Number of subjects: 244
Study 28514053 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental instruction (CDI)
Number of subjects: 244
Study 27472452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) for SPOV, 12 sessions
Number of subjects: 24
Study 27472452 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 24
Study 25296595 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX7 plus supplementation of tiopronin
Number of subjects: 150
Study 25296595 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX7 without tiopronin (Control)
Number of subjects: 150
Study 22516357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 2% chondroitin sulfate (20 mL, 8 weekly instillations)
Number of subjects: 98
Study 22516357 — intervention group
Group type: COMPARATOR
Intervention: Inactive control solution (20 mL, 8 weekly instillations)
Number of subjects: 98
Study 22516357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 2% chondroitin sulfate
Number of subjects: 98
Study 22516357 — intervention group
Group type: COMPARATOR
Intervention: Inactive control solution
Number of subjects: 98
Study 20150347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 units oxytocin
Number of subjects: 75
Study 20150347 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit oxytocin
Number of subjects: 75
Study 20150347 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 units oxytocin
Number of subjects: 75
Study 20150347 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 units oxytocin
Number of subjects: 75
Study 20150347 — intervention group
Group type: COMPARATOR
Intervention: 0 units oxytocin (placebo)
Number of subjects: 75
Study 20150347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 units oxytocin
Number of subjects: 75
Study 17567227 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive group (50% reduction in per-refill copayment)
Number of subjects: 200
Study 17567227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentive)
Number of subjects: 200
Study 16182834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 103)
Number of subjects: 205
Study 16182834 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine ME (n = 102)
Number of subjects: 205
Study 12517682 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 24
Study 12517682 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril 8 mg
Number of subjects: 24
Study 12517682 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 10 mg
Number of subjects: 24
Study 12517682 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 50 mg
Number of subjects: 24
Study 12517682 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 10859584 — intervention group
Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 600
Study 10859584 — intervention group
Group type: COMPARATOR
Intervention: Monitoring by family practitioners
Number of subjects: 600
Study 10859584 — intervention group
Group type: EXPERIMENTAL
Intervention: INR self-management training
Number of subjects: 600
Study 9038465 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulphate 10 mg orally pre-operatively
Number of subjects: 112
Study 9038465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1355693 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 223
Study 1355693 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse neuroleptics
Number of subjects: 223
Study 1355693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 223
Study 6487753 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of sodium salicylate (NaSA)
Number of subjects: 0
Study 6487753 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated tablet of sodium salicylate (NaSA)
Number of subjects: 0
Study 6487753 — intervention group
Group type: COMPARATOR
Intervention: Solution of sodium salicylate (NaSA)
Number of subjects: 0
Study 31365457 — intervention group
Group type: EXPERIMENTAL
Intervention: RTF (Repetition to Failure)
Number of subjects: 18
Study 31365457 — intervention group
Group type: EXPERIMENTAL
Intervention: NTF (Not to Failure)
Number of subjects: 18
Study 30852016 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic bolus (MSP)
Number of subjects: 148
Study 30852016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 148
Study 29288141 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of medications
Number of subjects: 181
Study 29288141 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depression scores
Number of subjects: 181
Study 29288141 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased Functional Reach Test (FRT) distance
Number of subjects: 181
Study 26540737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates intervention (36 training sessions over three months, 3 sessions a week)
Number of subjects: 88
Study 26540737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 24740025 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 tissue expanders
Number of subjects: 82
Study 24740025 — intervention group
Group type: COMPARATOR
Intervention: Saline expanders
Number of subjects: 82
Study 22302127 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral almorexant 200 mg
Number of subjects: 20
Study 22302127 — intervention group
Group type: COMPARATOR
Intervention: Intravenous almorexant 20 mg
Number of subjects: 20
Study 20571832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (200 mg) with 0.5 mg epinephrine
Number of subjects: 60
Study 20571832 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (200 mg) with 0.5 mg epinephrine
Number of subjects: 60
Study 20571832 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study 20571832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Levobupivacaine
Number of subjects: 60
Study 17902853 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure to EMFs emitted by GSM mobile phones
Number of subjects: 27
Study 17902853 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 27
Study 16043829 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d combined with carboplatin and paclitaxel
Number of subjects: 1059
Study 16043829 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with carboplatin and paclitaxel
Number of subjects: 1059
Study 16043829 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib for never smokers
Number of subjects: 1059
Study 16043829 — intervention group
Group type: COMPARATOR
Intervention: Placebo for never smokers
Number of subjects: 1059
Study 16043829 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib and placebo
Number of subjects: 1059
Study 12489063 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus AER (N = 18)
Number of subjects: 39